Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
Paul B. Chapman, Mark Klang, Michael A. Postow, Alexander Noor Shoushtari, Ryan J. Sullivan, Jedd D. Wolchok, Taha Merghoub, Sadna Budhu, Phillip Wong, Margaret K. Callahan, Bin Zheng, Jonathan Zippin · 2023
Read Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib by Paul B. Chapman, Mark Klang, Michael A. Postow, Alexander Noor Shoushtari, Ryan J. Sullivan, Jedd D. Wolchok, Taha Merghoub, Sadna Budhu, Phillip Wong, Margaret K. Callahan, Bin Zheng, Jonathan Zippin (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10695100.txt.
Description
Paul Chapman and co-authors test a diabetes drug as a boost for melanoma care, in work from 2023. Lab work hinted phenformin could deepen the kill of two targeted drugs in skin cancers with a V600 gene flaw. Eighteen patients with spread disease got the trio in a dose-climb trial.
Doses ran up to two hundred milligrams twice a day before the climb was cut short by the pandemic. Nausea and vomiting were most common, with two cases of a blood acid flaw that reversed. Ten patients responded, some after prior targeted care. A suppressor cell type fell in most high-dose patients. The team set a phase two dose of fifty milligrams.
Catalog record
| CREATOR | Paul B. Chapman, Mark Klang, Michael A. Postow, Alexander Noor Shoushtari, Ryan J. Sullivan, Jedd D. Wolchok, Taha Merghoub, Sadna Budhu, Phillip Wong, Margaret K. Callahan, Bin Zheng, Jonathan Zippin |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |